Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IWWM-11 2022 | The importance of testing for cryoglobulinemia in Waldenström’s macroglobulinemia patients

Shirley D’Sa • 29 Oct 2022
IWWM-11 2022
Lymphoma Non-Hodgkin Lymphoma Rare Diseases Waldenström’s Macroglobulinemia

In this video, Shirley D’Sa, MD, FRCP, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, highlights the importance of testing for cryoglobulinemia in patients with Waldenström’s macroglobulinemia (WM), and challenges in this space. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Janssen- speaker fees, research grants, congress support, advisory boards
BeiGene- speaker fees, research grants, congress support, advisory boards
Sanofi- speaker fees, advisory boards

More from Shirley D’Sa

1:03
Clinical outcomes of patients with WM treated with bortezomib in the UK R2W study
Shirley D’Sa • 29 Oct 2022
2:02
Therapeutic options available to patients with R/R Waldenström’s macroglobulinemia
Shirley D’Sa • 29 Oct 2022
1:58
Therapeutic agents being explored in Waldenström’s macroglobulinemia trials
Shirley D’Sa • 29 Oct 2022
1:27
Ibrutinib therapy for Waldenström’s macroglobulinemia: real-world experiences in the UK
Shirley D’Sa • 29 Oct 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals